ReviewJournal for immunotherapy of cancer2021

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.

Paul B Chapman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.